Interleukin-2 Plus Histamine Dihydrochloride in Treating Patients With Acute Myeloid Leukemia
Multi-Center, Randomized Open-Label Study to Evaluate the Safety and Efficacy of Immunotherapy With Subcutaneous Maxamine (Histamine Dihydrochloride) Plus Proleukin (Interleukin-2) Versus No Treatment (Standard of Care) in Patients With Acute Myeloid Leukemia in First or Subsequent Complete Remission (CR)
Sponsor: Maxim Pharmaceuticals
A PHASE3 clinical study on Leukemia, this trial is completed. The trial is conducted by Maxim Pharmaceuticals and has accumulated 6 data snapshots since 1998. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
Jul 1998
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Maxim Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aalborg, Denmark , Adelaide, Australia , Albuquerque, United States , Angers, France , Atlanta, United States , Auchenflower, Australia , Auckland, New Zealand , Augsburg, Germany , Berlin, Germany , Besançon, France and 101 more locations